Quanterix Corporation (QTRX)
NASDAQ: QTRX · Real-Time Price · USD
5.87
-0.46 (-7.27%)
Mar 3, 2026, 4:00 PM EST - Market closed
Quanterix Revenue
In the year 2025, Quanterix had annual revenue of $138.90M with 1.07% growth. Quanterix had revenue of $43.86M in the quarter ending December 31, 2025, with 24.73% growth.
Revenue (ttm)
$138.90M
Revenue Growth
+1.07%
P/S Ratio
1.98
Revenue / Employee
$294,898
Employees
471
Market Cap
275.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 138.90M | 1.48M | 1.07% |
| Dec 31, 2024 | 137.42M | 15.05M | 12.30% |
| Dec 31, 2023 | 122.37M | 16.85M | 15.96% |
| Dec 31, 2022 | 105.52M | -5.03M | -4.55% |
| Dec 31, 2021 | 110.56M | 24.18M | 27.99% |
| Dec 31, 2020 | 86.38M | 29.64M | 52.25% |
| Dec 31, 2019 | 56.73M | 19.10M | 50.76% |
| Dec 31, 2018 | 37.63M | 14.76M | 64.52% |
| Dec 31, 2017 | 22.87M | 5.29M | 30.08% |
| Dec 31, 2016 | 17.59M | 5.41M | 44.38% |
| Dec 31, 2015 | 12.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viemed Healthcare | 254.79M |
| RxSight | 134.48M |
| Owlet | 99.64M |
| Delcath Systems | 85.23M |
| Sight Sciences | 76.05M |
| 908 Devices | 65.05M |
| TriSalus Life Sciences | 40.21M |
| ClearPoint Neuro | 34.33M |
QTRX News
- 1 day ago - Quanterix Corporation (QTRX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025 - Business Wire
- 1 day ago - Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide - Business Wire
- 5 days ago - Quanterix to Participate in Upcoming Investor Conferences - Business Wire
- 11 days ago - Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 - Business Wire
- 4 weeks ago - Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection - Business Wire
- 5 weeks ago - Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling - Business Wire
- 6 weeks ago - Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire